Dr. John Cush RheumNow
2 years 10 months ago
Analysis of German RABBIT registry did not show more MACE events in pts w/ JAK inhibitors compared to other DMARDs. 154 MACE w/ 14203 Rx episodes (21218 Pt-Yrs). IRs were 0.68 JAKi, 0.62 TNFi, 0.76 bdMARDs and 0.95 csDMARDs; higher in CV risk pts https://t.co/2UZh4zQFEM https://t.co/VRX2Z8YBrC
Dr. John Cush RheumNow
2 years 10 months ago
FDA has approved another ustekinumab biosimilar (Wezlana) as being interchangeable for use in adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. https://t.co/zbQKjmKgZh https://t.co/UuTDRgCBIV
A JAMA systematic review and meta-analysis has showed the use of JAK inhibitors (JAKi) in immune-mediated inflammatory skin diseases was not associated with increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE) (compared to the placebo or active comparator cohorts).
Dr. John Cush RheumNow
2 years 10 months ago
FDA has approved secukinumab (Cosentyx) for use in adults w/ moderate to severe hidradenitis suppurativa. Recommended dose is 300 mg SC @ wk 0, 1, 2, 3 and 4 and then every 4 weeks thereafter. https://t.co/Pi6RbDbroG https://t.co/AWhbVj2QGa
Dr. John Cush RheumNow
2 years 10 months ago
FDA has approved Abatacept to Treat Juvenile Psoriatic Arthritis (JPsA) in patients aged 2 to 17 years. (JPsA) in patients aged 2 to 17 years. This expands the current indications for ABA use in RA, poly JIA, PsA, and GVHD. https://t.co/eAc8Dsyc3b https://t.co/uHJqhEvuPG
Dr. John Cush RheumNow
2 years 10 months ago
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today!
https://t.co/1SjBiM7Daj https://t.co/w2cFcj85r5
Dr. John Cush RheumNow
2 years 10 months ago
Choosing steroid sparing therapies in #PMR
We have no evidence-based alternative treatment to glucocorticoids in PMR. Few disease-modifying anti-rheumatic drugs, such as methotrexate and leflunomide, are used in daily clinical practice in PMR.
https://t.co/zvfAwc7t1z https://t.co/pAJFHF6hOn
Dr. John Cush RheumNow
2 years 10 months ago
Blinkers and the Unseen Information Gap in #PMR
https://t.co/uZ9qCPmRw9 https://t.co/lrXRdVGNk2
Dr. John Cush RheumNow
2 years 10 months ago
#PMR Mythbusters: PMR Gets 100% Better Within 72 hours
https://t.co/lezwD0J8pL https://t.co/QluGHHnH3X
The treatment of de Quervain tenosynovitis (DQT) was examined by systematic review in JAMA, suggesting that local (US-guided) corticosteroid injection plus a thumb spica immobilization was associated with significant pain-relieving and functional benefits.
Dr. John Cush RheumNow
2 years 10 months ago
Why should rheumatologists discuss exercise in #PMR?
https://t.co/DBnXetbu2K https://t.co/hfjugw661u
Dr. John Cush RheumNow
2 years 10 months ago
Metanalysis of 26 studies (2252) pts w/ HBsAg-/HBcAb+ RA treated with b/tsDMARDs, shows the pooled HBV reactivation rate was 2.0%
HBV reactivation higher w/ RTX (9%), ABA (6%), JAKi (1%); none w/ IL-6i or TNF-i
More reactivation if pt is HBsAb- (OR=4.56) https://t.co/fSqvkEGbw3 https://t.co/WGCoZ4nQ3d
Dr. John Cush RheumNow
2 years 10 months ago
FDA Approves Infliximab Biosimilar for Subcutaneous Use
Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease.
https://t.co/YnbisOzf0L https://t.co/9AyxEBpasb
Dr. John Cush RheumNow
2 years 10 months ago
Ph 3 360 pt RCT of sarilumab in #GCA was terminated early (COVID). 83 pts Rx'd, only 35%(29) completed. Sustained remission @wk 52:
- SAR 200: 6/13
- SAR 150: 3/7
- PBO: 0/6
All had 26wk GC taper
Sm sample size & COVID ruined RCT interpretation https://t.co/axOvJGpUti #PMR https://t.co/Xpabxn1IjZ
Dr. John Cush RheumNow
2 years 10 months ago
Subcutaneous Biosimilars?
Dr. Cush reviews RheumNow's top entries the #PMR Campaign, news, journal reports and regulatory actions.
https://t.co/BkKFbv0I64 https://t.co/EABeZxCKYZ
